Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors
November 28 2018 - 9:00AM
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that it has
appointed Scott Jackson, former Chief Executive Officer
of Celator Pharmaceuticals, Inc., to its Board of
Directors. Mr. Jackson served as Celator’s CEO and as a
member of its Board of Directors from April
2008 until July 2016, when the company was acquired by
Jazz Pharmaceuticals plc.
"As uproleselan advances in late-stage clinical trials in acute
myeloid leukemia (AML), Scott’s experience leading Celator through
the successful development of Vyxeos® for treatment of newly
diagnosed AML patients will be invaluable to GlycoMimetics,” said
Rachel King, GlycoMimetics’ Chief Executive
Officer. “His deep operational experience, including in sales,
marketing and commercialization, is directly relevant as we look
forward to potentially commercializing this novel drug
candidate.”
Mr. Jackson has more than 25 years of experience in the
pharmaceutical and biotechnology industry and has held positions of
increasing responsibility in sales, marketing and commercial
development at Eli Lilly & Co., SmithKline
Beecham, ImClone Systems Inc., Centocor Inc., a division
of Johnson & Johnson, Eximias Pharmaceutical and YM
BioSciences. He holds a B.S. in pharmacy from
the Philadelphia College of Pharmacy and Science and an
M.B.A. from the University of Notre Dame. Mr. Jackson
presently serves on the Board of Directors of MacroGenics, Inc. and
the Board of Trustees of the Eastern Pennsylvania Chapter
of The Leukemia and Lymphoma Society.
“I am excited to join the GlycoMimetics Board at a time when the
company is making tremendous strides in the development of
glycomimetic compounds, such as uproleselan for AML,” said Mr.
Jackson. “AML is an area of high unmet medical need and
uproleselan, if approved, could potentially make a significant
impact on the treatment of patients with AML. I look forward to
working with the Board and leadership team to advance this
important drug candidate and to leverage the potential of the
company’s broad pipeline.”
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company
focused on the discovery and development of novel glycomimetic
drugs to address unmet medical needs resulting from diseases in
which carbohydrate biology plays a key role. GlycoMimetics' most
advanced drug candidate, rivipansel, a pan-selectin antagonist, is
being developed for the treatment of vaso-occlusive crisis in
sickle cell disease and is being evaluated in a Phase 3 clinical
trial being conducted by its strategic collaborator, Pfizer.
GlycoMimetics' wholly owned drug candidate, uproleselan, an
E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial
as a potential treatment for AML and is currently being evaluated
in a company-sponsored Phase 3 trial in relapsed/refractory
AML. The U.S. Food and Drug Administration granted uproleselan
breakthrough therapy designation for the treatment of adult
AM) patients with relapsed/refractory disease.
GlycoMimetics has also completed a Phase 1 clinical trial with
a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin
antagonist. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more
at www.glycomimetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding the clinical development and
potential utility of the company’s drug candidates. Actual results
may differ materially from those in these forward-looking
statements. For a further description of the risks associated with
these statements, as well as other risks facing GlycoMimetics,
please see the risk factors described in the company’s quarterly
report on Form 10-Q filed with the U.S. Securities and Exchange
Commission (SEC) on November 2, 2018, and other filings
GlycoMimetics makes with the SEC from time to time. Forward-looking
statements speak only as of the date of this release, and
GlycoMimetics undertakes no obligation to update or revise these
statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181128005114/en/
Investor Contact:Shari AnnesPhone: 650-888-0902Email:
sannes@annesassociates.com
Media Contact:Jamie Lacey-MoreiraPhone:
410-299-3310Email: jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024